title: Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia.
abstract: BACKGROUND
  Artesunate derivative drugs are newly introduced antimalaria drugs developed in response to the increasing drug resistance malaria spread.
  
  
  OBJECTIVE
  To determine the parasitological resistance and the clinical failure to Artemether-Lumefantrin (Coartem); and artesunate plus sulfadoxine pyrimethamine (SP) by the WHO 14 day in vivo test.
  
  
  METHODS
  The WHO 14 day in vivo efficacy study for coartem and artesunate with sulfadoxine-pyrimethamine covered the period from Nov 28 to Dec. 26, 2006 with 141 patients of ages 2 - 35 years with uncomplicated malaria around the big hydroelectric power dam region of Gilgel Gibe II (GGII). There was close clinical follow up and included parasitic load and clearance. Packed red cell volume (Hematocrit) was measured at day 0 and 14.
  
  
  RESULTS
  Parasitological resistance (RI, RII, RIII) to Coartem; and artesunate plus SP was not observed. There was no early as well as late clinical failure. All patients had adequate clinical response. The prevalence of malarial anemia (Hct < 33%) was 14.9% at day 0 and had decreased to 7.5% by day 14 in both groups.
  
  
  CONCLUSIONS
  Coartem and artesunate with SP are highly efficacious in the treatment of uncomplicated malaria in the GGII hydroelectric dam area.
authors.affiliation: Department of Internal Medicine, AAU, Medical Faculty.
authors.forename: Teshale
authors.initials: T
authors.lastname: Seboxa
authors.forename: Paolo
authors.initials: P
authors.lastname: Mao
authors.forename: Natalia
authors.initials: N
authors.lastname: Pinchouk
authors.forename: Jobira
authors.initials: J
authors.lastname: Anbessie
authors.forename: Hailubeza
authors.initials: H
authors.lastname: Alemu
authors.forename: Ermias
authors.initials: E
authors.lastname: Diro
mesh_terms: D000293:Adolescent; D000962:Antimalarials / Q000627:therapeutic use*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000627:therapeutic use*; D000077332:Artesunate; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use*; D005002:Ethiopia; D005260:Female; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D005449:Fluorenes / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D018512:Parasitemia / Q000188:drug therapy / Q000469:parasitology; D010963:Plasmodium falciparum / Q000302:isolation & purification*; D011739:Pyrimethamine / Q000627:therapeutic use*; D018571:Sentinel Surveillance; D013413:Sulfadoxine / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; C001205:fanasil, pyrimethamine drug combination; D000077332:Artesunate; D013413:Sulfadoxine; D011739:Pyrimethamine